[{"id":"356b44d6-dd58-4331-be47-3289089beb92","acronym":"ALAFOSS-01","url":"https://clinicaltrials.gov/study/NCT06599502","created_at":"2025-02-25T13:56:50.654Z","updated_at":"2025-02-25T13:56:50.654Z","phase":"Phase 1/2","brief_title":"A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation","source_id_and_acronym":"NCT06599502 - ALAFOSS-01","lead_sponsor":"AstraZeneca","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12D","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab)"],"overall_status":"Recruiting","enrollment":" Enrollment 430","initiation":"Initiation: 10/18/2024","start_date":" 10/18/2024","primary_txt":" Primary completion: 01/20/2028","primary_completion_date":" 01/20/2028","study_txt":" Completion: 01/20/2028","study_completion_date":" 01/20/2028","last_update_posted":"2025-02-20"},{"id":"c0529000-1eea-42c3-9cae-d983a7189b6c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05943795","created_at":"2023-07-13T18:10:45.267Z","updated_at":"2025-02-25T15:36:23.229Z","phase":"Phase 3","brief_title":"A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma","source_id_and_acronym":"NCT05943795","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • BRAF mutation • HER-2 amplification • BRAF V600 • KRAS G12D • EGFR wild-type • RET mutation • ALK wild-type • ROS1 fusion • ROS1 rearrangement • RET rearrangement • KRAS G12 • KRAS amplification • NTRK fusion","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • BRAF mutation • HER-2 amplification • BRAF V600 • KRAS G12D • EGFR wild-type • RET mutation • ALK wild-type • ROS1 fusion • ROS1 rearrangement • RET rearrangement • KRAS G12 • KRAS amplification • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • izalontamab (SI-B001)"],"overall_status":"Recruiting","enrollment":" Enrollment 584","initiation":"Initiation: 07/14/2023","start_date":" 07/14/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-02-11"},{"id":"b13e6021-21ee-414a-b797-f317ed8e7f72","acronym":"3082-CL-0101","url":"https://clinicaltrials.gov/study/NCT05382559","created_at":"2022-05-19T11:56:18.696Z","updated_at":"2025-02-25T16:46:04.383Z","phase":"Phase 1","brief_title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","source_id_and_acronym":"NCT05382559 - 3082-CL-0101","lead_sponsor":"Astellas Pharma Inc","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12D • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12D • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • setidegrasib (ASP3082)"],"overall_status":"Recruiting","enrollment":" Enrollment 541","initiation":"Initiation: 06/08/2022","start_date":" 06/08/2022","primary_txt":" Primary completion: 10/31/2026","primary_completion_date":" 10/31/2026","study_txt":" Completion: 10/31/2026","study_completion_date":" 10/31/2026","last_update_posted":"2025-02-05"},{"id":"d78d7b46-d2cc-485a-8c04-81f9d73189d4","acronym":"KEYNOTE-E28","url":"https://clinicaltrials.gov/study/NCT04429542","created_at":"2021-01-18T21:20:02.191Z","updated_at":"2025-02-25T16:10:23.024Z","phase":"Phase 1","brief_title":"Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors","source_id_and_acronym":"NCT04429542 - KEYNOTE-E28","lead_sponsor":"Bicara Therapeutics","biomarkers":" PD-L1","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • KRAS G12D • EGFR amplification • PD-L1 negative • RAS wild-type • KRAS G12 • KRAS G13 • EGFR negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • KRAS G12D • EGFR amplification • PD-L1 negative • RAS wild-type • KRAS G12 • KRAS G13 • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ficerafusp alfa (BCA101)"],"overall_status":"Recruiting","enrollment":" Enrollment 292","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-01-27"},{"id":"97072759-d618-48d0-b29e-295d8bf2e9f2","acronym":"TRIAD1","url":"https://clinicaltrials.gov/study/NCT06667544","created_at":"2025-02-26T11:55:40.746Z","updated_at":"2025-02-26T11:55:40.746Z","phase":"Phase 1/2","brief_title":"A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation","source_id_and_acronym":"NCT06667544 - TRIAD1","lead_sponsor":"Ranok Therapeutics (Hangzhou) Co., Ltd.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12D","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12D"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 152","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-10-31"},{"id":"b7624b27-8c4e-4193-bab7-2c294ff4563f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06385925","created_at":"2024-04-26T14:50:24.450Z","updated_at":"2024-07-02T16:34:37.904Z","phase":"Phase 1/2","brief_title":"A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","source_id_and_acronym":"NCT06385925","lead_sponsor":"Tyligand Bioscience (Shanghai) Limited","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12D","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12D"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 04/29/2024","start_date":" 04/29/2024","primary_txt":" Primary completion: 10/30/2026","primary_completion_date":" 10/30/2026","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2024-06-06"},{"id":"1aa44e24-9704-4fe0-a608-34236855cfe0","acronym":"19-C-0017","url":"https://clinicaltrials.gov/study/NCT03745326","created_at":"2021-01-18T18:20:39.102Z","updated_at":"2024-07-02T16:34:38.005Z","phase":"Phase 1/2","brief_title":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients","source_id_and_acronym":"NCT03745326 - 19-C-0017","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • KRAS • ALK • NRAS • HRAS","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12D • NRAS G12 • HLA-A*11","tags":["EGFR • PD-L1 • KRAS • ALK • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12D • NRAS G12 • HLA-A*11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • anti-KRAS G12D mTCR PBL • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 05/16/2019","start_date":" 05/16/2019","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-06-05"},{"id":"b30a8bca-2be6-49b4-90f3-03ff7a00b1ad","acronym":"","url":"https://clinicaltrials.gov/study/NCT04586270","created_at":"2021-01-18T21:52:48.356Z","updated_at":"2024-07-02T16:34:37.959Z","phase":"Phase 1","brief_title":"A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer","source_id_and_acronym":"NCT04586270","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" HER-2 • KRAS • PTEN • NF1","pipe":" | ","alterations":" KRAS mutation • HR positive • KRAS G12C • HER-2 negative • KRAS G12D • NF1 mutation • KRAS G12 • HR positive + HER-2 negative","tags":["HER-2 • KRAS • PTEN • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • HR positive • KRAS G12C • HER-2 negative • KRAS G12D • NF1 mutation • KRAS G12 • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TAS0612"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 10/15/2020","start_date":" 10/15/2020","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-06-05"},{"id":"bce05c4f-6c6a-4884-8079-4fd16c00542d","acronym":"KISIMA-02","url":"https://clinicaltrials.gov/study/NCT05846516","created_at":"2023-05-06T14:04:12.085Z","updated_at":"2024-07-02T16:34:59.526Z","phase":"Phase 1","brief_title":"A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC (KISIMA-02)","source_id_and_acronym":"NCT05846516 - KISIMA-02","lead_sponsor":"Amal Therapeutics","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12D • KRAS G12V • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12D • KRAS G12V • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • ATP150 • ATP152 • Kisima (ATP128) • VSV-GP154"],"overall_status":"Recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 03/13/2023","start_date":" 03/13/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-06-03"},{"id":"edef415f-bd84-49a1-9a8c-360704fed600","acronym":"","url":"https://clinicaltrials.gov/study/NCT05786924","created_at":"2023-03-28T14:04:59.609Z","updated_at":"2024-07-02T16:35:02.207Z","phase":"Phase 1","brief_title":"A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers","source_id_and_acronym":"NCT05786924","lead_sponsor":"Black Diamond Therapeutics, Inc.","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • BRAF mutation • NRAS mutation • KRAS G12D • KRAS G12V • KRAS G12 • NRAS G12D","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • BRAF mutation • NRAS mutation • KRAS G12D • KRAS G12V • KRAS G12 • NRAS G12D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e S241656"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 04/18/2023","start_date":" 04/18/2023","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-05-21"},{"id":"2b7c4292-573a-4f4f-aeb9-0287544f452d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03592888","created_at":"2021-01-18T17:39:37.238Z","updated_at":"2024-07-02T16:35:05.451Z","phase":"Phase 1","brief_title":"DC Vaccine in Pancreatic Cancer","source_id_and_acronym":"NCT03592888","lead_sponsor":"University of Pennsylvania","biomarkers":" KRAS • HLA-A","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12R • HLA-A*03 • KRAS G12 • HLA-A*02 • HLA-A*11","tags":["KRAS • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12R • HLA-A*03 • KRAS G12 • HLA-A*02 • HLA-A*11"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 11/20/2018","start_date":" 11/20/2018","primary_txt":" Primary completion: 02/12/2024","primary_completion_date":" 02/12/2024","study_txt":" Completion: 02/12/2024","study_completion_date":" 02/12/2024","last_update_posted":"2024-05-07"},{"id":"d557545c-a8fc-4f7f-9d63-eb284cbe8b60","acronym":"AMPLIFY-7P","url":"https://clinicaltrials.gov/study/NCT05726864","created_at":"2023-02-14T18:02:24.073Z","updated_at":"2024-07-02T16:35:05.951Z","phase":"Phase 1/2","brief_title":"A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors","source_id_and_acronym":"NCT05726864 - AMPLIFY-7P","lead_sponsor":"Elicio Therapeutics","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • NRAS mutation • KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12 • KRAS G12S • NRAS G12D • NRAS G12 • NRAS G13 • NRAS G12S • NRAS G12V","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • NRAS mutation • KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12 • KRAS G12S • NRAS G12D • NRAS G12 • NRAS G13 • NRAS G12S • NRAS G12V"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ELI-002 7P"],"overall_status":"Recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 04/14/2023","start_date":" 04/14/2023","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-05-03"},{"id":"a0f9dd51-d692-4574-b05e-3f5caa78cfd2","acronym":"AMPLIFY-201","url":"https://clinicaltrials.gov/study/NCT04853017","created_at":"2021-04-21T11:53:35.333Z","updated_at":"2024-07-02T16:35:09.637Z","phase":"Phase 1","brief_title":"A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors","source_id_and_acronym":"NCT04853017 - AMPLIFY-201","lead_sponsor":"Elicio Therapeutics","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS G12D • KRAS G12 • NRAS G12D • NRAS G12","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS G12D • KRAS G12 • NRAS G12D • NRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ELI-002 7P • Promune (agatolimod)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 10/04/2021","start_date":" 10/04/2021","primary_txt":" Primary completion: 01/26/2023","primary_completion_date":" 01/26/2023","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-04-15"},{"id":"3eb84e3a-596a-4eb0-a2c6-ca4c30c42738","acronym":"NCI-2018-01441","url":"https://clinicaltrials.gov/study/NCT03608631","created_at":"2021-01-18T17:44:21.049Z","updated_at":"2024-07-02T16:35:10.185Z","phase":"Phase 1","brief_title":"iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation","source_id_and_acronym":"NCT03608631 - NCI-2018-01441","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12D • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12D • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Undisclosed MSC-derived Exosomes with KrasG12D siRNA"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/27/2021","start_date":" 01/27/2021","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-04-11"},{"id":"59c4433e-178c-41e8-bb65-1d9a0a1d95a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05631899","created_at":"2022-11-30T17:57:34.718Z","updated_at":"2024-07-02T16:35:20.773Z","phase":"Phase 1","brief_title":"CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors","source_id_and_acronym":"NCT05631899","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" KRAS","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • MSI-H/dMMR • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • MSI-H/dMMR • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • albumin-bound paclitaxel • cyclophosphamide • KRAS-EphA-2-CAR-DC"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 04/03/2023","start_date":" 04/03/2023","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2024-02-06"},{"id":"fe61047d-8ed4-4b77-a9be-8df7e1bcb409","acronym":"","url":"https://clinicaltrials.gov/study/NCT06040541","created_at":"2023-09-15T18:10:24.393Z","updated_at":"2024-07-02T16:35:21.224Z","phase":"Phase 1","brief_title":"Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors","source_id_and_acronym":"NCT06040541","lead_sponsor":"Revolution Medicines, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12D • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12D • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zoldonrasib (RMC-9805)"],"overall_status":"Recruiting","enrollment":" Enrollment 290","initiation":"Initiation: 09/07/2023","start_date":" 09/07/2023","primary_txt":" Primary completion: 08/30/2025","primary_completion_date":" 08/30/2025","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2024-02-01"},{"id":"ccf0a3d0-2d12-4172-9a35-f6327f190184","acronym":"","url":"https://clinicaltrials.gov/study/NCT05254184","created_at":"2022-02-24T14:52:57.088Z","updated_at":"2024-07-02T16:35:22.368Z","phase":"Phase 1","brief_title":"KRAS-Targeted Vaccine With Nivolumab and Ipilimumab for Patients With NSCLC","source_id_and_acronym":"NCT05254184","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G13D • KRAS G12R • KRAS G12A • KRAS G12 • KRAS G13","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G13D • KRAS G12R • KRAS G12A • KRAS G12 • KRAS G13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2024-01-24"},{"id":"84bcb047-48bf-41ab-8d01-d2bc5efa22fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05737706","created_at":"2023-02-21T15:01:29.871Z","updated_at":"2024-07-02T16:35:28.495Z","phase":"Phase 1/2","brief_title":"Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation","source_id_and_acronym":"NCT05737706","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12D • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12D • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MRTX1133"],"overall_status":"Recruiting","enrollment":" Enrollment 386","initiation":"Initiation: 03/20/2023","start_date":" 03/20/2023","primary_txt":" Primary completion: 08/30/2026","primary_completion_date":" 08/30/2026","study_txt":" Completion: 08/30/2026","study_completion_date":" 08/30/2026","last_update_posted":"2023-11-21"},{"id":"b981fcae-ee9d-4262-ac3e-1cf908d11d83","acronym":"","url":"https://clinicaltrials.gov/study/NCT05533463","created_at":"2022-09-09T15:54:57.974Z","updated_at":"2024-07-02T16:35:30.238Z","phase":"Phase 1","brief_title":"Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","source_id_and_acronym":"NCT05533463","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12D • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12D • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRS-4642"],"overall_status":"Recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 09/15/2022","start_date":" 09/15/2022","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2023-11-06"},{"id":"754f31b9-2621-4d8e-805c-acb364907f2f","acronym":"GO-005","url":"https://clinicaltrials.gov/study/NCT03953235","created_at":"2021-01-18T19:27:25.774Z","updated_at":"2025-02-25T14:28:22.357Z","phase":"Phase 1/2","brief_title":"A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens","source_id_and_acronym":"NCT03953235 - GO-005","lead_sponsor":"Gritstone bio, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS G12C • KRAS G12D • KRAS G13D • KRAS G12 • NRAS Q61 • NRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12C • KRAS G12D • KRAS G13D • KRAS G12 • NRAS Q61 • NRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • SLATE-KRAS"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 07/18/2019","start_date":" 07/18/2019","primary_txt":" Primary completion: 03/10/2023","primary_completion_date":" 03/10/2023","study_txt":" Completion: 03/10/2023","study_completion_date":" 03/10/2023","last_update_posted":"2023-09-13"},{"id":"39082f6c-8d92-4c46-9e0c-a8aeaf83e623","acronym":"","url":"https://clinicaltrials.gov/study/NCT05173805","created_at":"2021-12-30T14:55:47.563Z","updated_at":"2024-07-02T16:35:42.768Z","phase":"Phase 1/2","brief_title":"Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation","source_id_and_acronym":"NCT05173805","lead_sponsor":"Shanghai YingLi Pharmaceutical Co. Ltd.","biomarkers":" PD-L1 • KRAS • MSI • PD-1","pipe":" | ","alterations":" KRAS mutation • MSI-H/dMMR • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12","tags":["PD-L1 • KRAS • MSI • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • MSI-H/dMMR • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e YL-15293"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 150","initiation":"Initiation: 01/30/2022","start_date":" 01/30/2022","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2023-07-18"},{"id":"71b5ac1d-448a-4fe7-bdf6-62e302fd6938","acronym":"","url":"https://clinicaltrials.gov/study/NCT05438667","created_at":"2022-06-30T17:02:13.557Z","updated_at":"2024-07-02T16:35:42.685Z","phase":"Phase 1","brief_title":"TCR-T Cell Therapy on Advanced Pancreatic Cancer","source_id_and_acronym":"NCT05438667","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12D • KRAS G12V • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12D • KRAS G12V • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/07/2022","start_date":" 06/07/2022","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 05/30/2026","study_completion_date":" 05/30/2026","last_update_posted":"2023-07-18"},{"id":"b2c74ab4-c1bb-4e58-a7dd-cb64d3bac04a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05651269","created_at":"2022-12-15T15:58:36.795Z","updated_at":"2024-07-02T16:35:59.048Z","phase":"Phase 2","brief_title":"Milciclib in Combination With Gemcitabine in Advanced NSCLC","source_id_and_acronym":"NCT05651269","lead_sponsor":"Tiziana Life Sciences LTD","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G13D • KRAS G12A • KRAS G12 • KRAS G12S • KRAS G13","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G13D • KRAS G12A • KRAS G12 • KRAS G12S • KRAS G13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • milciclib (TZLS-201)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 03/15/2023","start_date":" 03/15/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2022-12-15"},{"id":"fc0527a0-93cb-423f-bc83-608fc7b18373","acronym":"","url":"https://clinicaltrials.gov/study/NCT05202561","created_at":"2022-01-21T13:53:43.259Z","updated_at":"2024-07-02T16:36:14.829Z","phase":"Phase 1","brief_title":"A Study of RNA Tumor Vaccine in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05202561","lead_sponsor":"First Affiliated Hospital Bengbu Medical College","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12D • KRAS G12V • HLA-A*11","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12D • KRAS G12V • HLA-A*11"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 03/10/2022","start_date":" 03/10/2022","primary_txt":" Primary completion: 01/19/2023","primary_completion_date":" 01/19/2023","study_txt":" Completion: 01/19/2024","study_completion_date":" 01/19/2024","last_update_posted":"2022-03-23"}]